Cardiovascular diseases are the leading cause of death worldwide, recording 18 million deaths every year: approximately 50,000 people die from these pathologies every day
Smart Clot is the unique technology for the assessment
of patient thrombotic and hemorrhagic risk
Smart Clot addresses the IVD market, one of the fastest-growing segments of the healthcare industry
Cardiovascular diseases are a broad group of pathologies which affect the heart and blood vessels include coronary arteries diseases (e.g. heart attack) and cerebrovascular diseases (e.g. stroke, aneurysm).
16.12 is a company consisting in a multidisciplinary team of highly-skilled specialists whose experience in several fields is pooled together with the aim of improving the quality of patient care.
Smart Clot is a diagnostic platform that allows the simultaneous assessment of platelet adhesion and aggregation and fibrin formation to assess patient thrombotic and hemorrhagic risk.